Calls
1
u/Slow-Sun-2779
Reddit r/stocks
Win Rate
100.0%
return
+77.5%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Feb 18
$8.45
+77.5%
Author claims Compass Pathways' COMP360, a psilocybin-derived therapy, showed statistically and clinically significant Phase 3 improvement in treatment-resistant depression patients who failed two or more antidepressants. The mechanism is that FDA approval and commercialization could let it treat millions of depression patients and earn billions annually, with historical breakthrough-therapy approval odds cited above 70% and potential big-pharma acquisition. The catalyst is FDA filing and possible approval/commercialization, with the author seeing 10x potential in a few years or within this year if a buyout occurs. Main stated risk: clinical trials take years and face rigorous regulation, and prior psychedelic stock hype faded.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Slow-Sun-2779 has 1 trade ideas tracked on Buzzberg across 1 tickers since February 2026. Most covered: CMPS.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
